Feng Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feng Kong has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Chunling Li
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
28 shared publications - Chunyan Wang
Department of Biochemistry and Molecular Biology, Shandong Tumor Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, P.R. China
28 shared publications - Dapeng Wang
School of Basic Medicine, Bengbu Medical University
28 shared publications - Fangmin Li
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
28 shared publications - Hongying Wang
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
28 shared publications - Huiwen Luan
Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Binzhou Medical University, Yantai, Shandong, China
28 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2628409
Functional urine production and glomerular maturation from embryonic metanephros transplanted at the renal hilum in rats
End-stage renal disease remains a major global health burden, and novel regenerative strategies are urgently needed. Embryonic metanephros transplantation has emerged as a promising approach, but the optimal site for engraftment and functional maturation is unclear. In this study, embryonic day 15.5 metanephroi with attached bladder (MNB) were transplanted into adult rats at three sites: the renal hilum, renal subcapsular space, and omentum. After four weeks, grafts were assessed for survival, vascularization, nephron differentiation, and functional urine production. Compared with subcapsular and omental sites, hilum transplantation yielded markedly improved graft revasculari-zation and glomerular maturation, as demonstrated by enhanced expression of podocyte and tubular markers, as well as reduced interstitial fibrosis. Importantly, transplanted kidneys at the hilum produced urine containing creatinine and urea nitrogen, confirming functional integration with the host. These findings highlight the renal hilum as a superior anatomical niche for embryonic kidney transplantation, providing enhanced vascular supply and a microenvironment conducive to functional maturation. This work provides foundational evidence for the translational potential of renal hilum implantation as a strategy to generate functional renal tissue in vivo.
- 29 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2628409
Open AccessFunctional urine production and glomerular maturation from embryonic metanephros transplanted at the renal hilum in rats
End-stage renal disease remains a major global health burden, and novel regenerative strategies are urgently needed. Embryonic metanephros transplantation has emerged as a promising approach, but the optimal site for engraftment and functional maturation is unclear. In this study, embryonic day 15.5 metanephroi with attached bladder (MNB) were transplanted into adult rats at three sites: the renal hilum, renal subcapsular space, and omentum. After four weeks, grafts were assessed for survival, vascularization, nephron differentiation, and functional urine production. Compared with subcapsular and omental sites, hilum transplantation yielded markedly improved graft revasculari-zation and glomerular maturation, as demonstrated by enhanced expression of podocyte and tubular markers, as well as reduced interstitial fibrosis. Importantly, transplanted kidneys at the hilum produced urine containing creatinine and urea nitrogen, confirming functional integration with the host. These findings highlight the renal hilum as a superior anatomical niche for embryonic kidney transplantation, providing enhanced vascular supply and a microenvironment conducive to functional maturation. This work provides foundational evidence for the translational potential of renal hilum implantation as a strategy to generate functional renal tissue in vivo.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
THP-1-igsf9-WT not -igsf9-KO cells inhibited T cell proliferation in vitro.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
THP-1-igsf9-WT not -igsf9-KO cells inhibited T cell proliferation in vitro.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 reversed the inhibition of T cells mediated by IGSF9-ECD.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 reversed the inhibition of T cells mediated by IGSF9-ECD.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in normal tissue array.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in normal tissue array.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in tumor tissue arrays by immunohistochemistry.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 expression was detected in tumor tissue arrays by immunohistochemistry.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Supplementary material and methods and Supplementary tables
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Supplementary material and methods and Supplementary tables
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 regained the activation of T cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Anti-IGSF9 regained the activation of T cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Mouse IGSF9 was detected before and after MC38 implantation.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Mouse IGSF9 was detected before and after MC38 implantation.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 itself did not affect tumor cell proliferation.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
IGSF9 itself did not affect tumor cell proliferation.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Human IGSF9 was detected in myeloid cells of peripheral blood from healthy donors and tumor patients.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
Human IGSF9 was detected in myeloid cells of peripheral blood from healthy donors and tumor patients.